According to the company, the interim results indicate that sequential treatment of plaque psoriasis with Clobex spray followed by Vectical ointment is effective in managing plaque psoriasis over a 12-week period.
Additionally, the interim results demonstrate that this sequential treatment regimen was well tolerated, with the most commonly reported side effects including mild to moderate pruritus, stinging and burning and telangectasias.
While both Clobex spray and Vectical ointment are indicated for the treatment of plaque psoriasis, this study was conducted to confirm the safety and efficacy of these products when used in a sequential regimen.
In this study, Clobex spray was used in the initial phase of the study to treat moderate to severe plaque psoriasis. For subjects sufficiently clear at the end of four weeks, Vectical ointment was applied twice-daily for eight weeks. Success was evaluated at week 12 based on overall disease severity scores.
Ron Gottschalk, medical director of Galderma, said: “We look forward to reporting the final results of this study, which are expected to be published early next year. We believe this study will confirm that Vectical ointment can help maintain, for at least eight weeks, much of the gains seen when a high potency corticosteroid is used to initially treat moderate to severe plaque psoriasis.”